IP Library Granted Patent US 10,240,185
Granted Patent B2
US 10,240,185 · App. 14/215,407 · Granted Mar 26, 2019

Compositions, kits and related methods for the detection and/or monitoring of

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,240,185
App. No.
14/215,407
Granted
Mar 26, 2019
Kind
B2
Abstract

Provided are compositions, kits, and methods for the identification of Salmonella . In certain aspects and embodiments, the compositions, kits, and methods may provide improvements in relation to specificity, sensitivity, and speed of detection.

Claims (20)

1. A method for detecting Salmonella in a sample, said method comprising a detecting step of detecting the presence or absence of a Salmonella target nucleic acid using a fluorescently labeled molecular torch oligonucleotide, wherein the molecular torch oligonucleotide comprises the nucleotide sequence consisting essentially of SEQ ID NO: 66, 67, 68, 69, or 70, and wherein the detecting step is performed below 60° C.

2. The method of claim 1 , wherein the Salmonella target nucleic acid is an amplicon that comprises a sequence corresponding to bases from about 164 to about 209 of SEQ ID NO: 150.

3. The method of claim 2 , wherein the method further comprises contacting the Salmonella target nucleic acid with a T7 provider oligonucleotide and a primer oligonucleotide to generate the amplicon, wherein the T7 provider oligonucleotide comprises a nucleotide sequence that is SEQ ID NO: 1, 3, 5, or 6, and wherein the primer oligonucleotide has a sequence that is SEQ ID NO: 35, 37, 38, 39, 40, 42, 43, 45, or 46.

4. The method of claim 1 , wherein the sample is a bioprocess stream where Salmonella is a known or suspected contaminant.

5. The method of claim 1 , further comprising purifying or enriching the Salmonella target nucleic acid from the sample prior to performing the step of detecting the Salmonella target nucleic acid.

6. The method of claim 5 , wherein the purifying or enriching step comprises contacting the sample with a target capture oligonucleotide comprising (i) a sequence-binding region that specifically hybridizes to a target sequence in the Salmonella target nucleic acid and (ii) an immobilized probe-binding region, wherein the immobilized probe-binding region joins to a binding partner on an immobilized probe to capture any Salmonella target nucleic acid hybridized to said sequence-binding region to a solid support.

7. The method of claim 6 , wherein said target capture oligonucleotide has a sequence that is SEQ ID NO: 71-76 or 77.

8. A composition for use in detecting Salmonella in a sample, said composition comprising (i) a molecular torch oligonucleotide comprising the nucleotide sequence consisting essentially of SEQ ID NO: 66, 67, 68, 69, or 70, (ii) an RNA polymerase, and (iii) a promoter oligonucleotide, wherein the molecular torch specifically hybridizes to a sequence within a Salmonella target nucleic acid.

9. The composition of claim 8 , wherein the Salmonella target nucleic acid is an amplicon that comprises a sequence corresponding to bases from about 164 to about 209 of SEQ ID NO: 150.

10. The composition of claim 9 , wherein the compositions further comprises a T7 provider oligonucleotide comprising a nucleotide sequence that is SEQ ID NO: 1, 3, 5, or 6, and further comprises a primer oligonucleotide comprising a nucleotide sequence that is SEQ ID NO: 35, 37, 38, 39, 40, 42, 43, 45, or 46.

11. The composition of claim 8 , further comprising a target capture oligonucleotide comprising (i) a sequence-binding region that specifically hybridizes to a target sequence in the Salmonella target nucleic acid and (ii) an immobilized probe-binding region.

12. The composition of claim 11 , wherein said target capture oligonucleotide has a sequence that is SEQ ID NO: 71-76 or 77.

13. A kit for use in detecting Salmonella in a sample, said kit comprising (i) a molecular torch oligonucleotide comprising the nucleotide sequence consisting essentially of SEQ ID NO: 66, 67, 68, 69, or 70 wherein the molecular torch specifically hybridizes to a sequence within a Salmonella target nucleic acid, (ii) an RNA polymerase, and (iii) a promoter oligonucleotide for isothermally amplifying the Salmonella target nucleic acid.

14. The kit of claim 13 , wherein the Salmonella target nucleic acid is an amplicon that comprises a sequence corresponding to bases from about 164 to about 209 of SEQ ID NO: 150.

15. The kit of claim 13 , wherein the kit further comprises T7 provider oligonucleotide comprising a nucleotide sequence that is SEQ ID NO: 1, 3, 5, or 6, and further comprises a primer oligonucleotide comprising a nucleotide sequence that is SEQ ID NO: 35, 37, 38, 39, 40, 42, 43, 45, or 46.

16. The kit of claim 13 , further comprising a target capture oligonucleotide comprising (i) a sequence-binding region that specifically hybridizes to a target sequence in the Salmonella target nucleic acid and (ii) an immobilized probe-binding region.

17. The kit of claim 16 , wherein said target capture oligonucleotide is selected from the sequences of SEQ ID NOs: 71-76 or 77.

18. The method of claim 1 , wherein the detecting step is performed in a reaction mixture comprising the molecular torch oligonucleotide, an RNA polymerase, and a promoter oligonucleotide.

19. The method of claim 1 , wherein the detecting step is performed as part of a real time amplification and detection method.

20. The method of claim 1 , wherein the detecting step is performed at about 42° C.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 14, 2019
From: HOLOGIC, INC.; CYNOSURE, LLC; CYTYC CORPORATION; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 050719/0701 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 032753/0942 Recorded Jun 3, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035813/0001 →
SECURITY INTEREST Recorded Apr 25, 2014
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK, USA
Reel/Frame 032753/0942 →